Efficacy of High-dose Liraglutide 3.0 mg in Patients with Poor Response to Bariatric Surgery: Real-world Experience and Updated Meta-analysis.
Federica VinciguerraCarla Di StefanoRoberto BarattaAlfredo PulvirentiGiuseppe MastrandreaLuigi PiazzaFabio GuccioneGiuseppe NavarraLucia FrittittaPublished in: Obesity surgery (2024)
Liraglutide 3 mg emerges as a viable option for significant weight loss in patients experiencing IWL or WR after BS. Its inclusion in a multimodal, sequential obesity treatment approach proves promising.
Keyphrases
- weight loss
- bariatric surgery
- high dose
- systematic review
- end stage renal disease
- ejection fraction
- obese patients
- roux en y gastric bypass
- chronic kidney disease
- newly diagnosed
- gastric bypass
- type diabetes
- insulin resistance
- peritoneal dialysis
- low dose
- prognostic factors
- randomized controlled trial
- meta analyses
- pain management
- patient reported outcomes
- adipose tissue
- glycemic control
- skeletal muscle
- replacement therapy